Systematic review of large neutral amino acids for treatment of phenylketonuria

Journal of Pediatric Biochemistry

Volumn 3, Issue 4, 2013, Pages 181-186

  Lindegren, Mary Louise ^a   Krishnaswami, Shanthi ^a   Reimschisel, Tyler ^a   Fonnesbeck, Christopher ^a   Sathe, Nila A ^a   McPheeters, Melissa L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

dietary supplements; neutral amino acids; Phenylketonuria; PKU

Indexed keywords

AMINO ACID DERIVATIVE; LARGE NEUTRAL AMINO ACID; PHENYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; ANXIETY; BLOOD BRAIN BARRIER; CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIETARY COMPLIANCE; DISEASE ASSOCIATION; HUMAN; PHENYLKETONURIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84893809324     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.3233/JPB-130091     Document Type: Review

References (14)

1. National Institutes of Health Consensus Development Con-ference Statement: Phenylketonuria: Screening and man-agement, October 16-18, 2000. Pediatrics 2001; 108(4): 972-82.
2. Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phe-nylketonuria: Dietary and therapeutic challenges. J Inherited MetabDis 2007; 30(2): 145-52.
3. van Spronsen FJ, de Groot MJ, Hoeksma M, Reijngoud DJ, van Rijn M. Large neutral amino acids in the treatment of PKU: From theory to practice. J Inherit Metab Dis 2010; 33(6): 671-6.
4. Rocha JC, Martel F. Large neutral amino acids supplemen-tation in phenylketonuric patients. J Inherit Metab Dis 2009; 32(4): 472-80.
5. van Spronsen FJ, Enns GM. Future treatment strategies in phenylketonuria. Mol Genet Metab 2009; 99 (SUPPL.): S90-S5.
6. de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phe-nylketonuria: Review of hypotheses. Mol Genet Metab 2009; 99 (SUPPL.): S86-S9.
7. Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr 2000; 159 Suppl 2: S109-13.
8. van Spronsen FJ, Hoeksma M, Reijngoud D-J. Brain dys-function in phenylketonuria: Is phenylalanine toxicity the only possible cause J Inherit Metab Dis 2009; 32(1): 46-51.
9. Sarkissian CN, Gámez A, Scriver CR. What we know that could influence future treatment of phenylketonuria. JInherit MetabDis 2009; 32(1): 3-9.
10. Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald JD, et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 2006; 29(6): 732-8.
11. Methods Guide for Effectiveness and Comparative Effec-tiveness Reviews. AHRQ Publication No. 10(12)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2012. Chapters available at: Www. effectivehealthcare.ahrq.gov.
12. Lindegren ML, Krishnaswami S, Fonnesbeck C, Reimschisel T, Fisher J, Jackson K, Shields T, Sathe NA, McPheeters ML. Adjuvant Treatment for Phenylketonuria (PKU) Rockville (MD): Agency for Healthcare Research and Qual-ity (US); 2012 Feb. ReportNo.:12-EHC035-EF. AHRQ Comparative Effectiveness Reviews
13. Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A et al. The effects of large neutral amino acid sup-plements in PKU: An MRS and neuropsychological study. Mol Genet Metab 2007; 91(1): 48-54.
14. Matalon R, Michals-Matalon K, Bhatia G, Burlina AB, Burlina AP, Braga C et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: Effect on blood phenylalanine. J Inherit Metab Dis 2007; 30(2): 153-8.